Printer Friendly

BAC and Octapharma announce collaboration expansion for G-CSF Custom Ligand.

M2 EQUITYBITES-17 August 2010-BAC and Octapharma announce collaboration expansion for G-CSF Custom Ligand(C)2010 M2 COMMUNICATIONS

BAC BV, a provider of antibody-based affinity purification technology, has entered into a licence agreement with Octapharma, an independent, global provider of human proteins for life-threatening diseases based in Switzerland.

Financial details of the license agreement announced today were not available.

Under the terms of the license, Octapharma can use BAC's G-CSF CaptureSelect custom affinity ligand for the purification of recombinant human granulocyte-colony stimulating factor (G-CSF) from human (HEK293F) cell cultures.

Existing G-CSF products are marketed as Filgrastim (E.coli derived) and Lenograstim (CHO derived).

This license reportedly follows success in an earlier collaboration (the feasibility study programme), in which BAC discovered and developed the anti-G-CSF ligand in close collaboration with Octapharma.

BAC BV was established in 1995 as a Unilever subsidiary (NYSE:UL; UN).

((Comments on this story may be sent to

COPYRIGHT 2010 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Aug 17, 2010
Previous Article:Kofax's software used by Australian BPO.
Next Article:Transactis selects InfoPrint solutions.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters